Professionally-oriented language training at the Institute for High Qualification Medical Staff Training and Professional Education of Bakoulev National Medical Research Center

Author(s):  
L.A. Boсkeria ◽  
M.B. Biniashvili ◽  
A.Yu. Klochkova
Author(s):  
A.M. Chukhrayov ◽  
◽  
N.S. Khodzhaev ◽  
M.B. Sarkizova ◽  
T.A. Lapshina ◽  
...  

The article describes the history of the creation of the Fyodorov Eye Microsurgery Federal State Institution from a problem laboratory to the present day, namely, functioning as a national medical research center. The final figures for medical and scientific work, educational activities are presented. The Fyodorov Eye Microsurgery Federal State Institution as an NMRC closely interacts with medical institutions of the assigned territories. cooperates closely with medical institutions in the assigned territories. Active benchmarking, continuous monitoring of ophthalmic care, analytical, organizational, methodological work, development of telemedicine. Each year, the Fyodorov Eye Microsurgery Federal State Institution performs more than 320 thousand operations and more than 1.5 million consultations. Over 35 years, about 25 million consultations and more than 7.5 million operations have been performed and more than 8 million patients have been treated. The share of the Fyodorov Eye Microsurgery Federal State Institution in the volume of ophthalmic surgical care provided in Russia is 37%. More than 15 thousand children undergo surgery in the centers for children of the Fyodorov Eye Microsurgery Federal State Institution every year. 35 years: 400 thousand foreign patients from 120 countries. A surge in online conferences. 2019: about four thousand conference participants. 2020: more than ten thousand. Institute of Continuing Professional Education with well-equipped WETLAB simulation operating rooms. Every year, 150 residents and postgraduates; training cycles – 600 ophthalmologists. Key words: history of the Fyodorov Eye Microsurgery Federal State Institution, national medical research center, benchmarking, Institute of Continuing Professional Education, WETLAB, medical tourism, socially significant diseases, children's center, mobile ophthalmological complexes


2018 ◽  
Vol 64 (3) ◽  
pp. 388-393
Author(s):  
Yekaterina Anokhina ◽  
V. Rubinchik ◽  
Yekaterina Yaremenko ◽  
Gulfiya Teletaeva ◽  
Dilorom Latipova ◽  
...  

Ipilimumab (IPI) provides a ten-year overall survival in almost 20 % of selected patients participated in several phase II-III trials. However, the expanded access program (EAP) looks more like routine practice than like clinical trials& This is why the results of such application could be different. Here we present the long-term follow-up data of single center EAP. Ninety-six patients with disseminated melanoma progressing after at least one lines of drug therapy were included at the N.N. Petrov National Medical Research Center of Oncology. Sixty-seven (70 %) patients had stage IV M1c, 35 patients (36 %) had elevated LDH before initiating IPI therapy. All patients received IPI 3 mg / kg IV every 3 weeks for a maximum of 4 cycles. Totally, 320 cycles (mean - 3.3 per patient) were conducted. Grade 3-4 immuno-mediated adverse events (imAE) observed in 18 (19 %) patients. Three patients died of adverse events, possibly associated with ongoing therapy. The median time to progression was 3 (95 % CI, 2.4 to 3.5) mo., the median overall survival was 13 (95 % CI, 8.3 to17.6) mo. Previous immunotherapy with dendritic cell vaccines decreased the risk of death by 48 % (Log-rank p = 0.049). The wild type BRAF status increased three-year overall survival from 29 to 68 % (p = 0.042). Our data confirms long-term safety and efficacy of IPI in patients with pretreated disseminated melanoma in the close to real practice setting.


2020 ◽  
Vol 19 (4) ◽  
pp. 20-31
Author(s):  
E. A. Litvin ◽  
D. T. Utalieva ◽  
D. Yu. Kachanov ◽  
A. V. Pshonkin ◽  
M. Ya. Yadgarov ◽  
...  

13-cis-Retinoic acid is a differentiation agent for neuroblastoma cells and is a part of post-consolidation therapy for high-risk patients. The effectiveness of this therapeutic approach is currently under study. 26 patients with high-risk neuroblastoma treated at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology were included in the study of 13-cis-Retinoic acid pharmacokinetics by high-performance liquid chromatography assay with ultraviolet detector depending on the method of administration of drug (swallowed capsules or opened capsules before administration). This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The current study showed that the therapeutic concentration of > 2 μM when taking 13-cis-Retinoic acid at a dose of 160 mg/m2/day was achieved in two groups, regardless of the method of drug administration. However, plasma concentrations of 13-cis-Retinoic acid at 4 hours after administration on the 14th day of therapy were higher in the group of patients who swallowed the capsules (4.1 ± 1.8 μM), compared to those who could not do it (1.9 ± 1.5 μM) (p = 0.022). The introduction into the clinical practice of therapeutic drug monitoring of 13-cis-retinoic acid in high-risk neuroblastoma patients with an assessment of peak concentration and dose adjustment of the following courses may be an important point in the attempt to optimize postconsolidation therapy and improve prognosis.


Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 210
Author(s):  
Aleksandra Asaturova ◽  
Darya Dobrovolskaya ◽  
Alina Magnaeva ◽  
Anna Tregubova ◽  
Guldana Bayramova ◽  
...  

Recent evidence suggests that a cytology–histology correlation (CHC) with discrepancy detection can both evaluate errors and improve the sensitivity and specificity of the cytologic method. We aimed to analyze the errors in cytologic–histologic discrepancies according to the CHC protocol guideline of the American Society of Cytopathology (2017). This retrospective study included 273 patients seen at the National Medical Research Center of Obstetrics, Gynecology and Perinatology (Moscow, Russia) between January 2019 and September 2021. The patients’ mean age was 34 ± 8.1 years. The cytology–histology agreement was noted in 158 cases (57.9%). Major discrepancies were found in 21 cases (7.6%), while minor discrepancies were noted in 93 cases (34.1%). The reason for 13 (4.8%) discrepancies was a colposcopy sampling error and, in 46 (16.8%) cases, the reason was a Papanicolaou (PAP) test sampling error. The discrepancy between primary and reviewed cytology was due interpretive errors in 13 (4.8%) cases and screening errors in 42 (15.4%) cases. We demonstrated that the ASC guidelines facilitate cervical CHC. A uniform application of these guidelines would standardize cervical CHCs internationally, provide a scope for the inter-laboratory comparison of data, and enhance self-learning and peer learning.


2021 ◽  
Vol 20 (2) ◽  
pp. 84-96
Author(s):  
E. A. Cherniak ◽  
N. E. Sokolova ◽  
K. V. Semiglazova ◽  
I. N. Lavrentyeva ◽  
E. K. Donush ◽  
...  

The article presents retrospective data analysis of a cohort of patients with PKD (n = 41 patients, aged 4 months – 26,5 years, median of age – 5 years 1 month) who were examined at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology for unspecifid hereditary hemolytic anemia during the period 2013–2020. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. In all patients, the diagnosis was confimed by Next Generation sequencing (NGS). The homozygous mutations in the PKLR gene were found in 10 patients (24.39%), compound heterozygous mutations in 31 patients (75.61%), 77.78% of them were missense mutations. Gender distribution (male:female) was 1:1.73. At least once transfusion of erythrocyte suspension was required to 40 (97.56%) patients. The minimum age at the time of the debut of transfusion dependence was the fist day of life, the maximum was 4 years. Exchange blood transfusion was performed in 13 children, severe normocytic hyperregenerative anemia with transfusion of red blood cells in the fist days of life was noted in 12 children, at the 1st month of life – in 9 children, at the 2nd month of life – in 8 children, at the 3rd month – in 6 children, at the 5th month – in 2 children, at the 1st year – in 1 child, and 2 children underwent single transfusions on the background of infectious episodes at 3 and 4 years respectively. Splenectomy due to high transfusion dependence was performed in 10 patients: transfusion independence was achieved in 5 patients, in 5 – an increase in the interval between blood transfusions. Median of surgical intervention (9 patients): 7 years 4 months, minimum age – 1 year 4 months, maximum – 14 years 4 months. In total, 36 genotypes were described in 41 patients, among them were: c.1529G>A in 3 patients, c.1137_1139del / c.1456C>T – in 2 patients, c.1079G>A/c.1529G>A in 2 patients, c.1130T>C/c.1456C>T in 2 patients, other genotypes occurred once. Two mutations were the most frequent: c.1456C>T (16.67%) and c.1529G>A (16.67%). 19 (46,34%) of patients had previously not described mutations.


2021 ◽  
pp. 18-24
Author(s):  
M. A. Eremushkin

В работе рассмотрены вопросы создания и деятельности лечебно-реабилитационного клинического центра «Юдино» — филиала Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр реабилитации и курортологии» Министерства здравоохранения Российской Федерации с начала его открытия (1988 г.) по текущее время, с указанием его бывших и настоящего руководителей, отмечены основные достижения и наработки, полученные в реабилитационном комплексе в прошлом и современные направления его деятельности


2021 ◽  
pp. 8-14
Author(s):  
M. A. Eremushkin

В работе рассмотрены вопросы создания и деятельности лечебно-реабилитационного клинического центра «Юдино» — филиала Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр реабилитации и курортологии» Министерства здравоохранения Российской Федерации с начала его открытия (1988 г.) по текущее время, с указанием его бывших и настоящего руководителей, отмечены основные достижения и наработки, полученные в реабилитационном комплексе в прошлом и современные направления его деятельности.


Author(s):  
А. Черняев ◽  
A. Chernyaev ◽  
П. Борщеговская ◽  
P. Borschegovskaya ◽  
С. Варзарь ◽  
...  

The article assesses the personnel situation in the field of domestic radiation therapy and nuclear medicine. Despite the fact that in recent years there has been a significant re-equipping of Russian medical centers with the latest devices, the quantitative indicators of medical equipment normalized for the number of residents of the country are still significantly inferior to the indexes other countries. And this problem is greatly aggravated by the insufficient number of specialists who can work on the equipment supplied. First and foremost, this refer to medical physicists who are responsible not only for ensuring the required accuracy when applying a dose of ionizing radiation to the tumor, but also for ensuring radiation safety when working with sources of ionizing radiation. A continuing vocational educational retraining program covering development, operation and application of high-tech systems for radiotherapy is being proposed. This program was developed and tested at the Department of Physics of Accelerators and Radiation Medicine of the Physical Faculty of M.V. Lomonosov Moscow State University with the support of the Rusnano Foundation for Educational Programs. The co-executors in the development and approbation of the Program were the National Medical Research Center of Radiology, A.I. Burnasyan Federal Medical Biophysical Center of the FMBA of Russia. Invited experts in the process of developing the Program were scientists and specialists of the Bauman MSTU, Tomsk Polytechnic University, NRNU MEPhI, N.N. Blokhin National Medical Research Center of Oncology. As a result of a professional educational program, the necessary professional skills for working as specialists in radiotherapy units and nuclear medicine centers are formed, which will successfully solve the problem of professional human resources for the clinical centers of Russia. The program was developed and successfully implemented at the Department of Physics of Accelerators and Radiation Medicine of the Physics Department of M.V. Lomonosov Moscow State University. The need to develop a program of assessment of medical physicists, which are working at the moment, is being considered. This will guarantee a high level of knowledge necessary for full participation in the medical process and making responsible decisions on the therapeutic use of radiation devices and ensuring radiation safety of patients and personnel.


Sign in / Sign up

Export Citation Format

Share Document